



## December 2016 Newsletter

Volume 4, Issue 12

### Letter from Dr. Christine Brezden-Masley

Happy Holidays,

As 2016 comes to an end, we hope that the CCTC has been a helpful resource over the past year to make referring your patients to newly emerging clinical trials easier than ever.

We greatly value any input, feedback, and suggestions in order to make your experience with the site as user-friendly as possible. E-mail us at [cometrials@smh.ca](mailto:cometrials@smh.ca) and we will be more than happy to assist.

Sincerely,  
**Dr. Christine Brezden-Masley**  
Founder, COMET Clinical Trials Consortium

### Letter from the Project Manager, Alexandra Moskalewicz

It has been another great year for COMET Trials, and we thank all our members for their continued support.

Feel free to share this newsletter with any cancer care colleagues that may be interested, as we are always happy to have new members join the CCTC network.

As always, please contact me at [cometrials@smh.ca](mailto:cometrials@smh.ca) any time with questions, comments or concerns.

Kind Regards,  
**Alexandra Moskalewicz**

### Trials of the Month

Type	Trial	Site	Type	Trial	Site
Breast	<a href="#">MAC.19</a>	London Health Sciences	GYN	<a href="#">PHL-093</a>	London Health Sciences Centre
CNS	<a href="#">Intelligence 1</a>	London Health Sciences	Lung	<a href="#">ATLANTIS</a>	Southlake Regional Health
GU	<a href="#">TIVO-3</a>	Odette Cancer Centre, London Health Sciences	Mel	<a href="#">MEC5</a>	London, Royal Victoria, Odette
Heme	<a href="#">Gilead-GS-US-339-0102</a>	Royal Victoria	GI	<a href="#">JVCZ</a>	St. Michael's Hospital

### Trials Snapshot

Trial Type	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Total
Imaging Study	2			1						3
Prevention			1				2			3
Observational	2			1						3
Radiation	4		3	4				4		15
Surgical Therapy	1	2		1	1	1		1		7
Systemic Therapy	16	2	13	15	7	1	2	14	7	77
Therapeutic			1	1			2			4
<b>Total Trials</b>	<b>25</b>	<b>4</b>	<b>17</b>	<b>23</b>	<b>8</b>	<b>2</b>	<b>6</b>	<b>19</b>	<b>7</b>	<b>112</b>



## Trials of the Month

Type	Acronym	Study Title	Description	Site (s)
Breast	<a href="#">MAC.19</a>	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neo-adjuvant Chemotherapy	<ul style="list-style-type: none"> <li>• Surgical Therapy</li> <li>• Any HER2</li> </ul>	London Health Sciences
CNS	<a href="#">Intelligence 1</a>	A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> </ul>	London Health Sciences Centre
GU	<a href="#">TIVO-3</a>	A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> <li>• Locally Advanced</li> <li>• Renal Cell Carcinoma</li> </ul>	Odette Cancer Centre, London Health Sciences
Heme	<a href="#">Gilead-GS-US-339-0102</a>	A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> <li>• Leukemia (CLL)</li> <li>• Refractory</li> </ul>	Royal Victoria Regional Health Centre
GYN	<a href="#">PHL-093</a>	A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> <li>• Adjuvant</li> </ul>	London Health Sciences Centre
Lung	<a href="#">ATLANTIS</a>	Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line	<ul style="list-style-type: none"> <li>• Small Cell Lung Cancer</li> <li>• Systemic Therapy</li> </ul>	Southlake Regional Health Centre
Mel	<a href="#">MEC5</a>	A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> <li>• Stage III/IV</li> </ul>	Odette Cancer Centre
GI	<a href="#">JVCZ</a>	Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma	<ul style="list-style-type: none"> <li>• Gastric Cancer</li> <li>• Metastatic (2nd line) or locally advanced</li> </ul>	St. Michael's Hospital





## Member & Trial Updates

**265+** members

**31** institutions

**112** accruing trials



Registered Members and Trials per Institution

Institution	Members	Trials
Cambridge Memorial Hospital	3	2
Grand River Hospital	8	1
Humber River Regional Hospital	5	1
Kingston General Hospital	3	5
Juravinski Cancer Centre	7	-
Lakeridge Health Corporation	20	14
London Health Sciences Centre	9	57
Mackenzie Health Hospital	5	-
Markham Stouffville Hospital	3	-
Mount Sinai Hospital	2	5
North York General Hospital	10	2
Odette Cancer Centre/Sunnybrook	54	28
Ontario Institute for Cancer Research	3	-
Ontario Hospital	1	-
Ottawa Hospital	2	-
Princess Margaret Cancer Centre	24	1
Quinte Health Care	1	-
Rouge Valley Health System	2	-
Royal Victoria Regional Health Centre	24	21
Scarborough General Hospital	1	-
Southlake Regional Health Centre	19	11
St. Joseph's Health Centre (Toronto)	4	-
St. Joseph's Healthcare (Hamilton)	4	-
St. Michael's Hospital	12	7
Sudbury Regional Hospital	1	-
Thunder Bay Regional	2	-
Toronto General Hospital	3	1
Toronto East General Hospital	5	-
Trillium Health Partners	16	-
William Osler Health Systems	4	-
Windsor Regional Hospital	1	-

## Acknowledgements

The CCTC has been funded by unrestricted educational grants from the following supporters:

